Celltrion: "Zimpendra Maintains Effectiveness Without Combination of Immunosuppressants"

Long-term Results of Phase 3 Clinical Study Presented at American Gastroenterological Association Meeting
Chairman Seo Jeong-jin Engages with Global Medical Professionals On-site

Celltrion announced on the 30th that its subcutaneous injection type (SC) autoimmune disease treatment 'Jimpentra (project name CT-P13 SC, generic name infliximab)' maintains its therapeutic effect even without the use of immunosuppressants.

Celltrion stated that from the 25th to the 30th (local time), it revealed the long-term post-analysis results of the global Phase 3 clinical trial of Jimpentra at the '2024 American College of Gastroenterology (ACG)' held in Pennsylvania, USA.

This result compared and analyzed the efficacy and safety between Jimpentra monotherapy and combination therapy with immunosuppressants from week 54 to week 102 in 192 Crohn's disease (CD) patients and 237 ulcerative colitis (UC) patients.

According to Celltrion, there was no significant difference in efficacy and safety between the Jimpentra monotherapy group and the immunosuppressant combination therapy group. The Jimpentra monotherapy group showed stable results in terms of anti-drug antibody conversion rate compared to the combination therapy group. Celltrion explained that anti-drug antibodies are antibodies produced in response to the immune reaction to the drug, which can reduce the drug's effectiveness when they occur.

A Celltrion official said, "Through these clinical results, the burden on patients and medical staff in treating intestinal diseases can be reduced, and side effects that may occur in combination therapy can be avoided, which will be a great advantage for patients." He added, "It is expected to play an important role in increasing prescriptions of Jimpentra and expanding market share in the US market in the future."

Meanwhile, Celltrion Chairman Seo Jung-jin visited the conference site and promoted the competitiveness of autoimmune disease treatments to key gastroenterologists worldwide, the company said.